Mycoplasma Testing Market Size, Share, Growth Analysis, By Product & Service(Assays, Kits, & Reagents (NAT Assays, Kits), By Technique(Nucleic Acid Testing, Enzyme-Linked Immunosorbent Assay, Staining, Other Techniques), By Application(Cell Line Testing, Virus Testing, End-Of-Production Cell Testing), By End User(Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutes, Cell Banks & Laboratories), By Region - Industry Forecast 2024-2031

According to the mycoplasma testing market forecast, North America led the market in 2023 with a revenue share of 39.04%. A combination of several factors leads to a high market share. Prevalence of respiratory disorders is also at a high level and the rising investment in biotechnology by major companies since its wide application in cancer research and developing novel biologics, vaccines, and drugs. Besides, through the development and integration of strict regulatory requirements, companies such as the FDA and the U.S. Department of Health and Human Services, in collaboration with the Centers for Disease Control and Prevention and the National Institutes of Health, continually advance standards on the testing of biological and microbiological safety of biomedical laboratories. 

Asia-Pacific is predicted to grow at the highest CAGR during the forecast period. It is expected that the future development prospects would be spurred by the implementation of biosafety quality improvement-friendly regulatory mandates adopted by the health care organizations. It is with better infrastructures in place and better maintenance at higher levels of product safety that it would be anticipated to have a positive effect on the adoption of mycoplasma testing under the National Biotechnology Development Strategy-through government-led initiatives toward becoming a prime industrial power. Moreover, these developments were expected to ensure the continued industrial growth in the pharmaceutical and biologics industries and to bring long-term health benefits to humans. Further scope for development is perceived with the fact that there exist biological safety specific guidelines for the given research areas which include cell culture and recombinant DNA research.